Nov 19, 2024 | Press Releases
High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolled Updated data intended to be submitted as part of a European Medicines Agency (EMA) Submission in Q4 2024 Complete response data in 100...
Nov 12, 2024 | Press Releases
CULVER CITY, Calif.–(BUSINESS WIRE)–Nov. 12, 2024– ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective...
Oct 24, 2024 | Press Releases
Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent of Africa Complete enrollment currently expected in Q1 2025 CULVER CITY, Calif.,...
Oct 21, 2024 | Press Releases
CULVER CITY, Calif., October 21, 2024 — Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton...
Sep 9, 2024 | Press Releases
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)...
Aug 12, 2024 | Press Releases
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical bladder cancer programs Filing process initiated with European Medicines Agency (EMA) for regulatory approval of...
